ILLUMINATE Trial

High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
ILLUMINATE Trial On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of ILLUMINATE Trial All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on ILLUMINATE Trial
CDC on ILLUMINATE Trial
ILLUMINATE Trial in the news
Blogs on ILLUMINATE Trial
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for ILLUMINATE Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

Raising HDL levels by a combination of torcetrapib, a CETP inhibitor, and atorvastatin, an HGM-CoA reductase inhibitor.

Dates

Start Date

August 23, 2004

End Date

Premature Termination on December 2, 2006. Data collection continued till July 15, 2007.